Stock Events

Stock Events

Cypherpunk Technologies 

$0.76
0
-$0.01-0.81% Thursday 20:00

Statistics

Day High
0.79
Day Low
0.72
52W High
3.7
52W Low
0.22
Volume
390,613
Avg. Volume
2,569,296
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2025
Q4 2025
Next
-0.24
0.15
0.53
0.92
Expected EPS
-0.0406
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYPH. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Leap Therapeutics' focus on cancer immunotherapies.
Merck
MRK
Mkt Cap214.76B
Merck is a leading competitor in the oncology market, particularly with its blockbuster cancer drug Keytruda, which competes directly with cancer therapies developed by Leap Therapeutics.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG, through its Genentech subsidiary, competes in the cancer treatment space, including immunotherapies that directly compete with Leap Therapeutics' pipeline.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a strong presence in the oncology sector, including immunotherapy treatments that rival Leap Therapeutics' cancer therapy developments.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse oncology portfolio that includes immunotherapies and targeted cancer treatments, competing with Leap Therapeutics' focus areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its Kite Pharma acquisition, competes in the cancer immunotherapy space, directly challenging Leap Therapeutics' therapeutic approaches.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a growing oncology and hematology portfolio that includes treatments which could compete with Leap Therapeutics' cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in developing a range of cancer treatments, including immunotherapies that could compete with Leap Therapeutics' products.
Novartis
NVS
Mkt Cap237.61B
Novartis has a strong focus on oncology, with a portfolio that includes cancer immunotherapies and targeted treatments that rival Leap Therapeutics' developments.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen subsidiary, develops a variety of oncology treatments, including immunotherapies that could compete with Leap Therapeutics' pipeline.

About

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Show more...
CEO
Mr. Douglas E. Onsi J.D.
Employees
52
Country
IL
ISIN
US52187K2006

Listings

XNAS
US
CYPH
F
DE
5MC.F
BOATS
BOATS
CYPH.BOATS

0 Comments

Share your thoughts

FAQ

What is Cypherpunk Technologies stock price today?▼
The current price of CYPH is $0.76 USD — it has decreased by -0.81% in the past 24 hours. Watch Cypherpunk Technologies stock price performance more closely on the chart.
What is Cypherpunk Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cypherpunk Technologies stocks are traded under the ticker CYPH.
When is the next Cypherpunk Technologies earnings date?▼
Cypherpunk Technologies is going to release the next earnings report on May 18, 2026.
What were Cypherpunk Technologies earnings last quarter?▼
CYPH earnings for the last quarter are 0.92 USD per share, whereas the estimation was -0.07 USD resulting in a +1,485.54% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does Cypherpunk Technologies have?▼
As of April 04, 2026, the company has 52 employees.
In which sector is Cypherpunk Technologies located?▼
Cypherpunk Technologies operates in the Health Care sector.
When did Cypherpunk Technologies complete a stock split?▼
Cypherpunk Technologies has not had any recent stock splits.
Where is Cypherpunk Technologies headquartered?▼
Cypherpunk Technologies is headquartered in Cambridge, IL.